Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986315 + Nivolumab With Chemotherapy in First-line Stage IV or Recurrent NSCLC
2022-503007-22-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of BMS-986315, nivolumab, cisplatin, carboplatin, pemetrexed and 1 more in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-503007-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503007-22-00.